POMPE-C Tool for Pulmonary Embolism Mortality
In the setting of a patient with known cancer who has been diagnosed with a pulmonary embolism, the POMPE-C can be used to estimate their mortality.
The POMPE-C Prediction Tool was risk stratifies patients diagnosed with pulmonary embolism and have active cancer.
- The POMPE-C prediction tool predicts mortality directly (at 30 days), not a risk category of mortality.
- Active cancer has been shown to be a risk factor for PE, but less so for cancer in remission.
- The POMPE-C has not been validated for incidental PE (PE found on imaging but without symptoms), though a small sample was identified and found to be low-risk overall.
- The POMPE-C may be more accurate in predicting outcome than the PESI Score in the setting of patients with active cancer.
- The POMPE-C has not yet been validated for selecting patients for outpatient management (though there is potential for future research).
- Risk stratification is a vital part of the evaluation of a patient diagnosed with PE.
- Most risk-stratification tools use cancer as a prognostic indicator, but no risk stratification tool exists for those patients with known cancer.
- Those patients that are determined to be low risk (score ≤5%) may warrant outpatient management (though this has not been validated).